13 Oct 2021

Lonza Tampa - Expansions in HPAPI for Oral Solid and Inhalation Technology

Our facilities in Tampa (FL) US are an integral component of Lonza’s design, development and manufacturing network for drug substances and specialized drug products. Working collaboratively with our customers, our Tampa team designs develops and manufactures oral solid and inhalation drug products. The site provides a full range of services, starting from the initial stages of product development including pre-formulation, formulation & process design, and analytical method development. These services extend into early phase clinical, late phase clinical, and commercial-scale production including packaging and distribution worldwide.

Tampa also serves as our US Center of Excellence for rapid first-in-human services utilizing Powder-in-Capsule (PIC) based on our proprietary Xcelodose® Precision Powder Micro-Dosing Technology to effectively increase speed-to-clinic initiatives.

  • Site accomplishments: PIC to Commercial (ALUNBRIG), DEV to Commercial
  • +$20M in renovation
  • Site center of excellence: FIH Initiatives for Speed to Clinic
  • Unit operations same for inhalation (XD, Harro)
  • Cross site case studies (TBD) – VISP/QT/TPA
  • Site expansion: Containment & Unit Operations
  • OEB levels and containment (multi-use, unit op specific)
  • Extension of service: Inhalation Testing
  • Leverage Bend CoE for inhalation development
  • Analytical capabilities employed 2021
  • This session was originally broadcast live as part of CPHI North America 2021

    Content provided by our supplier


    • CH
    • 2015
      On CPHI since
    • 5000+
    Company types
    Contract Service

    Other Content from Lonza (35)